Day: April 28, 2022

Posted on

Informa Pharma Intelligence and The American Society of Gene & Cell Therapy (ASGCT) Launches Gene, Cell & RNA Therapy Landscape Q1 2022 Quarterly Data Report

New Report Highlights Key Industry Trends in Pharmaceutical R&D

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) — Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, and The American Society of Gene & Cell Therapy (ASGCT), today announced the launch of the Gene, Cell & RNA Therapy Landscape Q1 2022 Quarterly Data Report. The Q1 2022 report assesses industry trends by examining approved gene, cell and RNA therapies, the pharmaceutical pipeline by company, most targeted therapeutic areas, and an overview of recent dealmaking and start-up funding.

Notable findings from the first quarterly report of the year include:

  • FDA Approvals – Since Q4 2021, one new genetically modified cell therapy has been approved and one new gene therapy has filed for approval. Carvykti, a CAR-T cell therapy developed by Legend Biotech and Johnson & Johnson, was approved for multiple myeloma in the U.S. and EtranaDez (etranacogene dezaparvovec), an AAV5 gene therapy developed by uniQure, was filed for approval in the EU and UK for hemophilia B.
  • Gene Therapy Pipeline Growth – Since Q1 2021, the gene therapy pipeline has increased by 16% with 3,579 therapies in development, ranging from preclinical through preregistration. A total of 1,986 gene therapies (including genetically modified cell therapies such as CAR T-cell therapies) are in development, accounting for 55% of gene, cell and RNA therapies; and 816 non-genetically modified cell therapies are in development, accounting for 22% of gene, cell and RNA therapies.
  • Most Targeted Therapeutic Areas – Oncology and rare diseases continue to be the top areas of gene therapy development in both the overall pipeline (preclinical to preregistration) and in the clinic (Phase I to preregistration). Development for rare diseases most commonly occurs in the oncology space, representing a majority of 52% compared to non-oncology rare disease gene therapy pipeline development.
  • Deal Making – A total of 123 deals were signed, a 15% decrease in volume from Q4 2021. Q1 2022 was the lowest quarter total within the last year, and acquisition and alliance volume quarter by quarter remained flat, while financings continue to trend down. Acquisitions were the only type of deal to increase in Q1 2022.
  • Start-up Financing – Start-up financing by gene, cell and RNA therapeutic companies remained steady in Q1 2022. A total of 15 companies raised seed or Series A financing, totaling an aggregate $507.8M. The overall deal-making total across alliance, acquisitions and financings saw a 15% decline. In the largest start-up financing, Cellino Biotech, a Harvard University spin-out, raised $80M to support its large-scale production of autologous and allogeneic cell therapies.

“Since we started putting these quarterly reports together in Q1 2021, we have seen the gene therapy pipeline steadily increase. Oncology and rare disease remain the most targeted therapeutic areas, and we continue to see a strong pipeline for CAR-T cell therapies for cancer indications,” said Ly Nguyen-Jatkoe, PhD, Executive Director, Americas, Informa Pharma Intelligence. “Rare diseases continue to be a focus for RNA therapies.”

“The continued approvals of gene and cell therapies has turned into one of the brightest spots in releasing this report each quarter,” said David Barrett, JD, CEO, the American Society of Gene & Cell Therapy (ASGCT). “With the approval of Carvykti in Q1 2022 and the ever-expanding pipeline, we’re exceptionally optimistic about the future of the field.”

All pipeline and trial insights were compiled using data from Pharma Intelligence’s Pharmaprojects™, and Trialtrove™, part of Citeline, which has been tracking global drug development since 1980. Deal, financing and catalyst data were derived from Biomedtracker™. For more information, or to view the current and past reports, visit Informa Pharma Intelligence or contact pharma@informa.com.

About The American Society of Gene & Cell Therapy (ASGCT)
The American Society of Gene & Cell Therapy (ASGCT) is the primary professional membership organization for scientists, physicians, patient advocates and other professionals with interest in gene and cell therapy.

Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies. ASGCT advances knowledge, awareness and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to benefit patients and society.

About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products — Datamonitor Healthcare™, Sitetrove™, Trialtrove™, Pharmaprojects™, Biomedtracker™, Scrip™, Pink Sheet™ and In Vivo™ — to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 400 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information, visit pharmaintelligence.informa.com

Media Contacts:
Diffusion PR for Informa Pharma Intelligence
informapharma@diffusionpr.com

Alex Wendland for The American Society of Gene & Cell Therapy (ASGCT)
AWendland@asgct.org

Posted on

Delphix Accelerates Growth, Profitability for Second Consecutive Year at Scale

Data Security, Compliance Drive Urgent Adoption of Delphix DevOps Test Data Management Platform

REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) — Delphix, the industry leader in DevOps test data management (TDM), today announced closing fiscal year 2022 with a second consecutive year of accelerated revenue growth and profitability at a scale well over $100M in annual recurring revenue (ARR).

With increasing activity from hostile nation states and ransomware gangs, companies around the world need a solution to automate and secure test data for enterprise applications. As a result, the company also reported 36% faster year-over-year growth of its large, enterprise customer base driven by increasing data risks.

Delphix’s growth comes as companies around the world continue to invest in innovative DevOps solutions to accelerate application delivery, modernize legacy infrastructure, and move applications across the multicloud. Delphix offers the only DevOps TDM platform that automates the delivery of secure, compliant data for test and development, enabling up to 10x faster innovation.

“Enterprise applications all need test data for fast, quality releases,” said Jedidiah Yueh, Delphix Founder and CEO. “But test data has traditionally been slow, complex, and filled with risk. Delphix helps companies like Banco Carrefour, The University of Manchester, and BNP Paribas release applications quickly while improving data security and compliance.”

Banco Carrefour in Brazil utilizes the Delphix DevOps Data Platform to accelerate application releases while ensuring data security and compliance with privacy regulations such as Brazil’s General Data Protection Law (LGPD). Delphix empowers development teams with 320x faster data availability for financial reporting and analytics, enables faster application releases, and helps save 70% on storage.

Delphix delivers an innovative API-first data platform that transforms application delivery with comprehensive data controls. By automating data delivery into test environments, Delphix helps software developers innovate faster while reducing compliance and security risk.

Delphix also helps companies recover faster from ransomware attacks by continuously protecting data and making historical data immutable.

“We selected Delphix, because we like the technology as a tool to move data efficiently from one place to another, to reconstruct, to travel to the past,” said Yves Caseau, Group Chief Digital & Information Officer at Michelin. “If we look at what we’ve done, we used Delphix to move data from our Exadata server legacy to community Linux servers to get more scalability and lower cost.”

“We are also using Delphix as a way to accelerate innovation and set up new test and development environments faster. We can get all the appropriate data very fast with a few pointers and a few clicks and have a virtual transfer of the data as opposed to a physical one,” Caseau added.

Test data management is a critical component of application development but is often slow and manual. The Delphix DevOps Data Platform enables teams to create, manage, and automate hybrid cloud-based data environments to support CI/CD pipelines and train AI/ML algorithms.

“Compliant test data is the lifeblood of DevOps and ensuring continuous access to it is key for enterprises to accelerate application delivery,” said Jim Mercer, Research Director of DevOps and DevSecOps at IDC. “With digital transformation becoming increasingly essential for enterprises to compete across today’s marketplaces, we continue to see the need for modern TDM solutions across multiple industries.”

Delphix Growth Highlights

Delphix also introduced multiple innovations across the company’s product offerings in last fiscal year, including:

About Delphix

Delphix is the industry leader for DevOps test data management.

Businesses need to transform application delivery but struggle to balance speed with data security and compliance. Our DevOps Data Platform automates data security, while rapidly deploying test data to accelerate application releases. With Delphix, customers modernize applications, adopt multi-cloud, achieve CI/CD, and recover from downtime events such as ransomware up to 2x faster.

Leading companies, including Choice Hotels, Banco Carrefour, and Fannie Mae, use Delphix to accelerate digital transformation and enable zero trust data management. Visit us at www.delphix.com. Follow us on LinkedIn, Twitter, and Facebook.


Josh Harbert     
Chief Marketing Officer   |   Delphix
913.972.6180
Posted on

MMEX RESOURCES CORP. AND THE PROVINCE OF TIERRA DEL FUEGO ARGENTINA JOINTLY ANNOUNCE THE POTENTIAL DEVELOPMENT OF A GREEN HYDROGEN PROJECT FROM WIND POWER IN RÍO GRANDE, PROVINCE OF TIERRA DEL FUEGO, ARGENTINA

FORT STOCKTON, TEXAS, April 28, 2022 (GLOBE NEWSWIRE) — Today, the Province of Tierra del Fuego and MMEX jointly announce the potential development of a green hydrogen project in the Río Grande area.

The Governor of the Province of Tierra del Fuego, Mr. Gustavo Adrian Melella, announced that, “MMEX, a North American company with operations in Texas USA with extensive experience in the implementation, financing and operation of energy infrastructure in Latin America and the USA, is evaluating a project for the production of 55 tons of green hydrogen with 160 megawatts of base wind power.”

Governor Melella added, “The excellent wind conditions in the Río Grande area, which allow efficient logistics and production and direct access to the sea, are the basis for MMEX’s entry into Argentine Patagonia. The final objective would be the implementation of a green hydrogen node destined to export to Europe and Asia. We welcome and support the participation of MMEX in Tierra del Fuego.”

Jack W. Hanks, the CEO of MMEX stated, “We are very excited to join the Government of Tierra del Fuego to plan this project. The global focus on renewable energy and the need to reduce the planet’s carbon footprint is at the core of Tierra del Fuego and MMEX’s strategy, drawing on MMEX’s green hydrogen expertise.”

Hanks added, “Since 1989, in Texas and Peru, MMEX has built and operated thermoelectric plants, oil and gas pipelines, oil refineries and ethanol plants. It has also explored and operated oil and gas fields. MMEX, in conjunction with Siemens Energy, recently completed a front-end engineering design study for the production of 55 tons per day of hydrogen for this project and its other projects in Texas. Hydrogen can be transformed into Ammonia or Methanol for global exports. It is estimated that the investment will be in the range of US $500 million, generating up to 1,500 jobs in the construction stage and 300 qualified and permanent jobs in the operation stage.”

Hanks further commented, “Siemens Energy is a leading manufacturer of electrolysis equipment that enables the transition to clean energy. MMEX has also signed a memorandum of understanding with Siemens Energy and Siemens Gamesa, one of the world leaders in the production of wind towers, which is associated with the realization of this project. This will allow defining the necessary wind turbine and the required land to implement a 160MW wind farm that supplies electrical energy to the Siemens electrolysers to produce hydrogen.”

Governor Melella added, “The province of Tierra del Fuego and MMEX have signed agreements on the exchange of technical information. This allows rapid progress in the preliminary assessment of wind potential.”

The provincial government, within its support for the development of renewable energy industries, welcomes initiatives that allow the sustainable use of Tierra del Fuego’s resources and reaffirms, as a government, its commitment to sustainable development, the preservation of the environment, investment and employment.

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, which could cause our actual results to differ materially from those described in the forward looking statements. These risks include but are not limited to the Company’s ability to continue as a going concern, our lack of revenues, general business conditions, the requirement to obtain significant financing to pursue our business plan, our history of operating losses and other risks detailed from time to time in the Company’s SEC reports. In particular, readers should note MMEX undertakes no obligation to update forward-looking statements.

Kristen Quinn
MMEX Resources Corporation
kristen@paigepr.com
Posted on

Philips and Prisma Health sign multi-year, long-term strategic partnership to innovate healthcare across the enterprise and unlock the power of patient data

April 28, 2022

South Carolina’s largest health system adopts Philips software solutions for patient monitoring and enterprise imaging, helping to drive interoperability and data analytics, and deliver on Quadruple Aim

Amsterdam, the Netherlands and South Carolina, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Prisma Health, South Carolina’s largest non-profit healthcare system, today announced they have entered into a multi-year agreement to help the health system achieve enterprise interoperability, standardize patient monitoring, and drive innovation in enterprise imaging solutions to enhance patient care and improve clinical performance. As South Carolina’s largest private, non-profit healthcare system, and second-largest private company, Prisma Health wants to deliver on the quadruple aim: improve patient and staff satisfaction, lower costs, and improve outcomes for all South Carolinians.

Prisma Health was formed in 2017 when Greenville Health System and Palmetto Health, two of South Carolina’s most highly regarded healthcare systems, came together as one organization. Today, Prisma Health has nearly 3,000 licensed beds and 18 acute care and specialty hospitals, as well as 270 physician practices servicing 21 counties. They treat over one million unique patients across their networks each year, including 368,000 virtual care visits, and just under half a million emergency department visits.

“When our two regional healthcare organizations merged, an enterprise-wide technology strategy became critical to standardize best practices across the whole system, creating new bridges between hospital and home care and continuing to drive innovation,” said Rich Rogers, Senior Vice President, Chief Information Officer, Prisma Health.  “At Prisma Health, we wanted to engage a partner to help us address data integration and unlock the power of patient data so that we are able to provide our patients with the best care anywhere in our service areas. We want to put the right tools into the hands of our clinicians to allow them to better share information, collaborate and help transform care for the communities we serve.”

With the Philips HealthSuite secure cloud platform at its foundation, Philips is committed to enterprise interoperability. Philips’ solutions portfolio includes real-time patient monitoring, therapeutic devices, telehealth, image management and informatics solutions including radiology and cardiology PACS, advanced visualization, vendor neutral archive (VNA) and Philips Enterprise Viewer – Vue Motion, and interoperability solutions, including the industry-leading Philips Capsule Medical Device Information Platform. Prisma Health will not only have access to these technologies, they will also be the largest installation of the Philips Enterprise Performance Analytics – Performance Bridge – analytics platform in North America. Performance Bridge gives healthcare professionals access to near real-time data on departmental performance through an easy-to-use interactive dashboard. Vendor agnostic, Performance Bridge unifies information across different imaging modalities and informatics solutions to optimize organizational efficiency, drive adherence to standards of care and facilitates additional revenue streams. Prisma Health plans to use Performance Bridge to drive innovation and monitor their delivery of quality healthcare.

“At Philips, we made a deliberate decision to create an end-to-end enterprise strategy that will help our customers overcome interoperability barriers and enable data sharing,” said Vitor Rocha, Chief Market Leader for Philips North America. “Health systems shouldn’t have to worry about integrating technology, which is why we have developed vendor-agnostic solutions based on standards and frameworks that bring together data from applications, systems, and devices. This allows our partners to focus on what is most important to them and their patients – continuously improving the patient journey and outcomes.”

Long-term strategic partnerships (LSPs) are a growing trend within hospitals and health systems to better manage the cost and complexity of their technology investments over a defined period of time, while expanding quality access to advanced medical care to improve patient outcomes. Philips is a leader in LSPs and continues to work with forward-thinking organizations like Prisma Health to develop standards, best practices, and predictive technologies that can redefine the future of healthcare.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel.: +31 631 639 916
E-mail: mark.groves@philips.com

Silvie Casanova
Philips North America
Tel.: +1 781 879 0692
E-mail: silvie.casanova@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Prisma Health
Prisma Health is a non-profit health company and the largest healthcare system in South Carolina. With nearly 30,000 team members, 18 acute and specialty hospitals, 2,947 beds and more than 300 outpatient sites with nearly 2,000 physicians, Prisma Health serves more than 1.5 million unique patients annually in its 21-county market area that covers 50% of South Carolina. Prisma Health’s goal is to improve the health of all South Carolinians by enhancing clinical quality, the patient experience and access to affordable care, as well as conducting clinical research and training the next generation of medical professionals. Visit PrismaHealth.org for more information.

Attachment

Posted on

Leading Supply Chain Visibility Platform FourKites Awarded ISO 27001 Certification and Meets Standards for ISO 27017 and 27018

Enterprise-grade cloud security and data privacy gives FourKites customers and partners additional peace of mind

FourKites Awarded ISO 27001 Certification and Meets Standards for ISO 27017 and 27018

Enterprise-grade cloud security and data privacy gives FourKites customers and partners additional peace of mind

CHICAGO, April 28, 2022 (GLOBE NEWSWIRE) — Leading real-time supply chain visibility platform FourKites® today announced it meets the standards set by the International Standards Organization (ISO) for ISO 27017 for cloud service security and ISO 27018 for data privacy as part of its ISO 27001 certification. The achievement represents FourKites’ ongoing pursuit of the most recent and stringent security standards in the industry.

To qualify, an independent audit committee confirmed that FourKites meets a stringent set of requirements around security and privacy. ISO 27017 provides guidelines for information security controls applicable to and specific to the provisioning and use of cloud services, while ISO 27018 establishes commonly accepted controls and guidelines for implementing measures to protect personally identifiable information (PII) for the public cloud computing environment. Meanwhile, ISO 27001 mandates controls for the establishment, maintenance and certification of an information security management system (ISMS).

“Meeting these standards is a testament to FourKites’ ongoing commitment to go above and beyond when it comes to securing our platform, which ingests more than 250 terabytes of data each month,” said Mathew Elenjickal, FourKites Founder and CEO. “Safe and secure data sharing has tremendous benefits across the supply chain, including more accurate business planning and risk mitigation, higher customer satisfaction and retention, and improved employee morale.”

Adherence to ISO 27017 and 27018 is the latest validation of FourKites’ rigorous security efforts, including its comprehensive General Data Protection Regulation (GDPR) privacy program, which even applies in regions where it is not required and incorporates the Schrems II ruling.

“Our supply chain customers and partners around the globe can rest assured that FourKites uses the strongest and most secure standards in the industry to protect their valuable data,” added Elenjickal.

FourKites delivers real-time insights to customers around the globe, leveraging patented artificial intelligence based on 150 factors, including ​​weather, traffic and real-time data from GPS, ELD telematics networks, mobile devices, AIS and more. The company offers out-of-the-box dashboards and reports, automated and customizable notifications that leverage geofencing and temperature tracking, and SKU-level visibility to track multimodal shipments, even when they’re split across multiple carriers.

In Spring 2021, FourKites was awarded a patent for its groundbreaking Smart Forecasted Arrival (SFA) solution, which provides companies with highly frequent and accurate estimated times of arrival for over-the-road freight in transit — even when a truck lacks any technology to transmit location data. SFA is now available to FourKites customers globally, extending the benefits of real-time visibility to freight that would otherwise be invisible to modern supply chain management solutions.

About FourKites
FourKites® is the #1 global supply chain visibility platform, extending visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 185 countries, FourKites combines real-time data and powerful machine learning to help companies digitize their end-to-end supply chains. More than 1,000 of the world’s most recognized brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

Media Contacts
Marianna Vyridi
Big Valley Marketing for FourKites
(650) 468-3263
mvyridi@bigvalley.co

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5ed752ac-3bf9-4eaf-bb8b-e08ba31b326d


Copyright © 2022 GlobeNewswire, Inc.

Posted on

Hong Kong to be gateway for CMR Surgical in APAC region

Hong Kong to be gateway for CMR Surgical in APAC region

  • CMR Surgical to expand commercial roll out in world leading surgical robotic market
  • Leading teaching hospitals in Hong Kong – CUHK Medical Centre and Gleneagles Hospital – have introduced Versius

Cambridge, United Kingdom. 28 April 2022 00:01 (GMT). CMR Surgical – the global surgical robotics business – has today announced the introduction of the Versius® Surgical Robotic System in Hong Kong at CUHK Medical Centre (CUHKMC) and Gleneagles Hospital Hong Kong (GHK). CUHKMC was the first hospital in Hong Kong to introduce Versius where it is being used as part of a multidisciplinary robotic programme, including general surgery and urology. At Gleneagles, Versius has been used first in gynaecologic surgery, with plans to expand into general surgery and others as part of a multispecialty programme.

With Versius, both CUHKMC and GHK are offering robotic assisted surgery directly to patients through state-of-the-art specialty centres, bringing accessible surgical care to more patients. With one of the longest life expectancies in the world, Hong Kong’s healthcare sector is a global leader in utilising high tech equipment and surgical solutions for patients, presenting a significant opportunity for Versius to be widely adopted in private and public hospitals. APAC will be a major growth engine for surgical robotics where rapid digitalisation, rising demand and access to healthcare innovation will drive further adoption of health technology and innovations like Versius.

Per Vegard Nerseth, Chief Executive Officer of CMR Surgical said: “We have eagerly awaited our launch in Hong Kong to offer the city’s world leading healthcare system access to pioneering new technology, I am thrilled that we have entered such a robust and innovative market. Hong Kong will be our springboard to the rest of APAC as we prepare for further developments in the region in due course and continue to set CMR Surgical on the global stage.”

Dr Patrick Lau, Deputy Executive Director of the Hong Kong Trade Development Council commented: “Hong Kong is a leader in embracing innovation and technology, including in Healthcare. A novel robotic system such as Versius that will positively impact patients fits perfectly into this mould. We are delighted that CMR has chosen Hong Kong as the launchpad for the Asia Pacific region as we believe that Hong Kong offers biotechnology companies an ideal springboard from which to expand into rapidly growing markets in Mainland China, Asia and around the world.”

While the benefits of keyhole surgery for patients such as shorter recovery time, less pain and a lower risk of surgical site infections are well recognised, traditional manual keyhole surgery can be difficult to perform, leading many complex procedures to be performed via open surgery.i Surgical robotic systems such as Versius provide increased accuracy, precision and dexterity for surgeons, allowing for more surgical procedures to be more easily performed through keyhole surgery. The size, portability and versatility of Versius has made it popular with hospitals and surgeons around the world and has made Versius a cornerstone in enabling more keyhole surgery.

Kin Cheung, Head of Far East of CMR Surgical said: “The impact of the pandemic has been felt across healthcare systems globally, and Hong Kong is no exception to this. With Hong Kong’s can-do spirit as their guide, hospitals are looking for innovative solutions that help to address this strain while providing accessible technology options to their patients. We are delighted to be partnering with leading hospitals, CUHK Medical Centre and Gleneagles Hospital Hong Kong, to expand the benefits of robotic keyhole surgery. It is great to see Versius standing out in Hong Kong and offering world leading surgeons a very different surgical robotic option. CMR will continue to expand our presence in Hong Kong in order to fulfil our customers’ growing demand.”

CMR has designed an agile commercial and pricing model to suit all global markets, increasing access for many people to minimal access (keyhole) surgery. The value of innovation Versius offers as a leading-edge robotic technology, fits well within an innovative and diverse healthcare ecosystem like Hong Kong’s and other markets in the APAC region.

To further invest into the market, CMR has partnered with leading training centre, the CUHK Jockey Club Minimally Invasive Surgical Skills Centre (Jockey Club MISSC), located within the Prince of Wales Hospital, to deliver training and professional education to surgical teams. The introduction of Versius in Hong Kong follows CMR Surgical’s expansion into a number of markets across Europe, Middle East, India and Australia where the system is being used to perform surgical procedures across a range of surgical specialities including gynaecology, colorectal surgery, thoracic, general surgery and urology.

— ENDS —

Media Contacts:

If you wish to see more, please contact CMR Surgical at:

Press Office, CMR Surgical
T +44(0) 1223 755801
E pressoffice@cmrsurgical.com

Notes to editors:

The Versius® Surgical Robotic System

Versius® resets expectations of robotic surgery. Versius fits into virtually any operating room set-up and integrates seamlessly into existing workflows, increasing the likelihood of robotic minimal access surgery (MAS). The small, portable and modular design of Versius allows the surgeon to only use the number of arms needed for a given procedure.

Biomimicking the human arm, Versius gives surgeons the choice of optimised port placement alongside the dexterity and accuracy of small fully-wristed instruments. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the open surgeon console has the potential to reduce stress and fatigue and allows for clear communication with the surgical team. By thinking laparoscopically and operating robotically with Versius, patients, surgeons and healthcare professionals can all benefit from the value that robotic MAS brings.

But it’s more than just a robot. Versius captures meaningful data with its wider digital ecosystem to support a surgeon’s continuous learning. Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

About CMR Surgical Limited

CMR Surgical (CMR) is a global medical devices company dedicated to transforming surgery with Versius®, a next-generation surgical robot.

Headquartered in Cambridge, United Kingdom, CMR is committed to working with surgeons, surgical teams and hospital partners, to provide an optimal tool to make robotic minimal access surgery universally accessible and affordable. With Versius, we are on a mission to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care.

Founded in 2014, CMR Surgical is a private limited company backed by an international shareholder base.

i EUR Urol, Journal of Endourology, BMJ

Posted on

ITA Airways Launches the Summer Season in the American Market With Six Daily Flights Between the United States and Italy

ITA AIRWAYS LAUNCHES THE SUMMER SEASON IN THE AMERICAN MARKET WITH SIX DAILY FLIGHTS BETWEEN THE UNITED STATES AND ITALY

Pierfrancesco Carino, V.P. ITA Airways International Sales, is pictured during a presentation in New York celebrating the launch of the company’s summer season with 6 daily flights between Italy and the U.S.A., including New York, Miami, Boston and Los Angeles, on Wednesday, April 27, 2022. ITA Airways is the new Italian national carrier which started its operations in October 2021 and is now offering flights during the summer months to 64 destinations, of which 7 are intercontinental, 23 national and 34 international. (Stuart Ramson/AP Images for ITA Airways)

A Total of 42 Weekly Flights by the End of August

Presentation Event in New York Yesterday

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) — Yesterday, at the Glasshouse Chelsea in New York, ITA Airways, the new Italian national carrier presented to representatives of the American and International press as well as business partners in the US market the new connections with the American hubs launched with the 2022 summer season. The Company aims at offering six daily flights between the United States and Italy by June, to meet the travel needs of tourists and business passengers.

With flight operation available since October 15, 2021, ITA Airways is an efficient and innovative air carrier that will be a reference point in providing Italy with quality connectivity with domestic, international, and intercontinental destinations, thus boosting tourism and foreign trade. This will result courtesy of a strategy that focuses on the best customer service, combined with digitalization and sustainability, declined in its environmental, social and governance aspects.

The development of the intercontinental network represents one of the main assets of the Company, a strategy that will be consolidated also thanks to the arrival at the end of May of the new, latest generation Airbus A350 aircraft, which will join the Airbus A330 already operating in the fleet since the start of the summer season on long-haul destinations.

In particular, the focus of the expansion of ITA Airways’ routes for this summer is the US market, which is the most strategic market after Italy, as well as the one with the highest number of Italian Americans. In fact, by the beginning of June, ITA Airways’ program for the US market will be completed: in addition to the routes to New York, Miami and Boston – already operational with direct flights from Rome and Milan Malpensa (New York only) – the program includes the opening of Los Angeles, from June 1, with a direct flight from Rome Fiumicino.

The first flight from Rome Fiumicino to Miami started on March 1, followed by the Rome Fiumicino – Boston connection, operating since March 2, and the Milan Malpensa – New York JFK flight launched on April 2, which completed the offer on New York already ensured by the flight from Rome Fiumicino operated from last winter, now including two round-trip flights to JFK.

In addition to these five connections already operating to North America, a new destination from Rome Fiumicino to Los Angeles will be added in June, bringing the offer from Italy to the United States to a total of six daily flights.

The launch of the new routes consolidates the process of expansion in the US market, which aims to reach a total of 42 weekly flights between the United States and Italy by August. Moreover, through the code share agreement signed last year with Delta, there are more than 100 domestic destinations that ITA Airways customers can access through the hubs in the domestic network of the American company, with 40 destinations served through New York JFK and an array of equally important connections from Boston, Miami, and Los Angeles offered to meet the needs of business and leisure customers.

Moreover, the multiple offers of the Rome Fiumicino hub will allow ITA Airways to be the reference carrier from the United States to Italy and via Rome to Europe and the Mediterranean for the Italian community and the main communities of the Mediterranean countries.

In fact, the 2022 ITA Airways summer season will also feature the most popular Mediterranean destinations with new flights to the islands of Italy, including Sardinia served from both Rome Fiumicino and Milan Linate, as well as Spain, Greece and Croatia, and seasonal flights in August from Rome FCO and Milan Linate to Lampedusa, Pantelleria, Corfu, Heraklion, Rhodes, Ibiza, Menorca, and Majorca. Also, in August the destinations of Kefalonia, Dubrovnik and Split will be served from Rome FCO and Thessaloniki from Milan Linate.

The summer season will also see the addition of new flights from Rome Fiumicino to Buenos Aires and São Paulo starting from early June. These new routes will enable ITA Airways to expand into South America, which has always been a preferred destination for Italian holidaymakers and a country with the largest populations of Italian origin, as well as very important destinations alongside the United States for business and freight traffic.

The centrality of the US market in ITA Airways’ strategy is also reflected in the important marketing campaigns launched in recent months in New York, Boston, and Miami, with billboards in the landmarks of American tourism, including Time Square.

The U.S. market is also of primary importance for ITA Airways’ Cargo development strategy, given the importance of import and export traffic flows between Italy and the United States and the demand for related transport services by manufacturing companies, with reference to Made in Italy manufacturing and the transport of pharmaceutical products. The expansion of the number of flights and the portfolio of U.S. destinations, therefore, enriches the ITA Airways cargo offer, with direct and connecting transport solutions to and from the main cities in the United States and Europe, which will be further strengthened with the progressive use of the latest generation Airbus A330 and A350 aircraft, featuring greater load capacity and lower CO2 emissions.

The local presence is also ensured by the ITA Airways domestic team that works with travel agencies, trade partners, and web to ensure coverage of the main customer segments including business, leisure and VFR traffic. ITA Airways’ Cargo team in the United States works with major freight forwarders and in partnership with leading GSSAs, providing customers with all services for the organization and management of shipments.

Finally, thanks to the strong commercial partnership established with the major trade partners and corporates, ITA Airways ensures the full distribution of its flights covering each passenger segment in the United States.

Launched in early March, ITA Airways’ 2022 summer season includes 64 new destinations, of which 23 are domestic, 34 are international and 7 are intercontinental. Thanks to code share agreements with the major international carriers, ITA Airways is continuing to grow its network via partnerships with other global carriers – giving a privileged access route to the markets of greatest interest for the Company, firstly and foremostly in Europe and America, but also in Africa and Saudi Arabia.

Codeshare agreements enable ITA Airways to reach the entire domestic network of other international carriers with direct flights from Rome Fiumicino and Milan Linate to their hubs. In all, 24 codeshare agreements have been signed so far, for a total of over 270 destinations served on which ITA Airways will use its own codes.

All ITA Airways flights can be purchased on the ita-airways.com website, from the ITA Airways Call Center, or from travel agencies and airport ticket offices.

Volare Programme
With a commitment to maximum customer focus, ITA Airways launched on October 15, 2021 “Volare”, its new loyalty program, which is also accessible to American customers. It has been designed as an open ecosystem of services and products, made available by ITA Airways and its partners to ensure that customers have a unique, 360 ° travel experience of maximum value. Since March, the program has been enriched with new features that increase its flexibility and ease of use and offer frequent flyers everything they could desire from a program dedicated to them.

Volare is widening its strength based on the four values on which it was developed: ‘Freedom’, ‘Personalization’, ‘Choice’, and ‘Connection’:

Volare is a ‘made to measure’ program that consists of four exclusive Clubs, on an upward scale of increasing levels of premiumness and dedicated priority services: these are Smart, Plus, Premium and Executive. With every purchase on ITA flights, customers can accumulate the points they need to upgrade to the higher Club level and take advantage of various benefits and premium services. Furthermore, beginning from Club Smart, as the access threshold increases, the advantage for the customer also increases in terms of multipliers and the services available.

There are already many subscribers to Volare, both from Italy and abroad. To date, the program has more than 361,500 members, of which over 40,000 are Elite members (i.e. Club Plus, Premium and Executive). This result is also important because it is consolidated on the international market: suffice to say that 35% of the participants in the Status Match campaign came from foreign companies.

For more information:
LaPresse SpA Communication and Press Office Director
Barbara Sanicola – barbara.sanicola@lapresse.it

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/63b5e0e5-c979-4d7c-bebd-e492203668bc

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.


 

Posted on

Philips launches offering of Green and Sustainability Innovation Notes and a Series of Liability Management Transactions

April 28, 2022

THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL, OR ANY SOLICITATION OF AN OFFER TO PURCHASE, ANY SECURITIES OF PHILIPS.

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the intention to issue one or more series of notes (the “Notes”) under its European Medium Term Note (EMTN) program (the “EMTN Offering”), as well as a series of liability management transactions, which are expected to extend the company’s debt maturity profile.

With these transactions, Philips aims to leverage current financial market conditions to further optimize its debt maturity profile and liabilities. Once completed these transactions are expected to have a neutral impact on the amount of debt outstanding.

The net proceeds of the Notes will be used for Eligible Projects in accordance with Philips Green and Sustainability Innovation Bond Framework. Pending the full allocation of the net proceeds of the Notes, Philips intends to optimize its short-term treasury liquidity profile by applying such net proceeds towards the following liability management transactions, all of which are subject to the successful completion of the EMTN Offering:

  • A tender offer for certain series of its outstanding U.S. Dollar-denominated bonds due 2025 and 2026;
  • A tender offer for certain series of its outstanding Euro-denominated notes due 2023, 2024 and 2025 (the “Euro Tender Offer”);
  • The proposed make-whole redemption of any of the Euro-denominated notes due 2023 and 2024 that are not purchased in the Euro Tender Offer (the “Euro Make-Whole Redemption”); and
  • The proposed agreement with the relevant counterparties for early settlement of the outstanding forward contracts entered into in the third quarter of 2021 under the share buyback program for capital reduction purposes announced on July 26, 2021 (the “Early Forward Settlement”). The acquisition of 19,571,218 shares through the settlement of these forward contracts would result in the early completion of the repurchase program. Philips would then expect to cancel a total of approximately 28.3 million shares (including shares acquired through open market purchases in December 2021 and January 2022 under the aforementioned share buyback program) in the course of 2022, representing 3.3% of Philips’ currently outstanding shares.

Any decision by Philips to redeem outstanding bonds in the Euro Make-Whole Redemptions, or to complete the Early Forward Settlement, will depend on various factors at that time.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 5977055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the EMTN Offering, the USD Tender Offer, the Euro Tender Offer, the Euro Make-Whole Redemption and the Early Forward Settlement. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Important Information
This announcement is for informational purposes only and does not constitute or form part of any offer or invitation to sell, or any solicitation of an offer to purchase, any securities of Philips.  The securities offered in the EMTN Offering have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.  Neither the EMTN Offering nor the Euro Tender Offer is being made and will not be made directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality (including, without limitation, facsimile transmission, telex, telephone, email and other forms of electronic transmission) of interstate or foreign commerce of, or any facility of a national securities exchange of, or to owners of the subject securities who are located or resident in the United States or to U.S. Persons as defined in Regulation S of the Securities Act.

In the United Kingdom, this announcement is being distributed to, and is directed at, only (a) persons who have professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”); or (b) high net worth companies, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The Notes are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Notes will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents.
Manufacturer target market (MIFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs or UK PRIIPs key information document (KID) has been prepared as not available to retail in EEA or UK.

Posted on

Private Wealth Management Perspectives Series Finds That Rigorous Due Diligence Standards of Caribbean CBI Nations Earn International Respect: CS Global Partners

LONDON, April 28, 2022 (GLOBE NEWSWIRE) — The Financial Times’ Private Wealth Management (PWM) magazine recently hosted a virtual panel discussion on the impact of global risks on countries with Citizenship by Investment (CBI) programmes.

The virtual discussion features a distinguished panel of experts from major intelligence agencies including Karen Kelly, director of strategy and development at Exiger; Eddy Leviton, chief operating officer at Fact WorldWide and Heyrick Bond Gunning, chief operating officer at S-RM.

Yuri Bender, editor in chief Professional Wealth Management magazine moderated the panel.

The third instalment offers a rich discussion which contrasts different jurisdictions and investigates whether standards of due diligence processes are fairly consistent across the board and highlights programmes that are more rigorous, making their citizenships more valuable and better respected internationally.

Karen Kelly, director of strategy and development at Exiger said “We find that countries who are already engaging top due diligence intelligence companies have consistent standards across their CBI programmes.

“When looking at countries which are top rated, such as those in the Caribbean, we see that they are doing more in upscaling their programmes so that they are not just meeting minimum standards. Their CBI Units are always trying to achieve best practices by asking their due diligence agents on a regular basis how they can improve their risk-based approach, how they can evaluate applicants better and they are actively involved in the due diligence process from beginning to end.”

Kelly noted that she was more concerned about CBI programmes that are not transparent about their processes because it is highly likely that they are not as rigorous as they should be.

Comprehensive due diligence processes should involve levels of due diligence – CBI Units should be engaging with intelligence agencies as well as with their regional and international law enforcement counterparts to enable information sharing. Many well-regarded programmes are increasingly mandating their immigration and marketing agents to carry out minimum Know Your Customers due diligence on applicants at a basic level before they put them forward to the CBI Units.

When asked about fast-track CBI applications and whether they were as stringent as the ‘normal’ applications, Eddy Leviton, chief operating officer at Fact WorldWide commented that if a CBI Unit is carrying out all its due diligence processes correctly, then the fast-track application process would also be just as stringent.

“There’s so only so much you can do to speed up the due diligence process. This is because you have to do in-country verifications, you have to check all the documentation provided, verify it and double verify. You also have to cross reference a lot of different sources, so there is only so much time you can squeeze on producing a report.

“I have to reiterate that when you read a report produced by an intelligence firm, it is like reading the life story of a person – it is a biography from when an applicant was born, who they have mixed with, where they have worked – and to produce a document like that takes time. We can expedite reports, but you can only squeeze so much time otherwise the quality suffers,” added Leviton.

Thanks to a “rich tapestry of information” provided to intelligence firms and the information gathered through continuous monitoring, CBI Units are able to cross-reference and triple check any documents they receive from applicants and give a view on the veracity of information provided added Heyrick Bond Gunning, chief operating officer at S-RM.

The Caribbean continues to improve its due diligence standards making their programmes internationally recognised and respected.

International respect is vital for any CBI programme to thrive as many nations, especially in the OECS region, use CBI funds to fast-track economic transformational opportunities.

“Caribbean countries are on an ongoing drive to continuously enhance the due diligence of their programmes as they are very keen to protect the integrity and value of these programmes,” notes Paul Singh, Director at CS Global Partners – a leading citizenship planning firm.

He continues “CBI is enabling many of these nations to be independent and not rely on international aid which can be difficult to come by for Small Island Developing Nations.”

Funds from CBI programmes often provide a vital source of income for some countries, especially in times of crisis – as is often the case for Caribbean countries devastated by hurricanes – these countries value the investment that goes into their economies, and the benefits to their people.

The due diligence standards in the Caribbean region are some of the most effective in minimising perceived and actual security risks and these countries offer citizenship by investment programmes with notable track records. St Kitts and Nevis’ Programme was established in 1984 and Dominica’s Programme was established in 1993 as an example.

Professional Wealth Management, from the FT Group, is the premier resource for private banking and mutual fund coverage in Europe, Asia and beyond.

Watch the series here: https://video.pwmnet.com/

r@csglobalpartners.com
www.csglobalpartners.com
+447824029952

Posted on

Charli D’Amelio ดาราโซเชียลมีเดียชื่อดัง เตรียมร่วมแสดงให้กับค่าย Proxima Media ของ Ryan Kavanaugh ในแฟรนไชส์ภาพยนตร์ใหม่ ‘Home School’

นี่เป็นภาพยนตร์ของ Proxima เรื่องที่สองที่จะเข้าจดทะเบียนในตลาดหลักทรัพย์บันเทิง (ESX.io) ให้แฟน ๆ ได้สนับสนุนภาพยนตร์เรื่องนี้ได้

ซึ่งตั้งแต่การเปิดเผยภาพยนตร์เรื่อง ‘The Six Sense’ เป็นต้นมา ก็ไม่เคยทำให้ผู้ชมตกใจกับการประกาศได้ถึงขนาดนี้มาก่อน

ลอสแองเจลิส, April 28, 2022 (GLOBE NEWSWIRE) — Home School เป็นภาพยนตร์เรื่องแรกในแฟรนไชส์ภาพยนตร์ระทึกขวัญเหนือธรรมชาติจำนวน 8 เรื่อง นำแสดงโดย Charli D’Amelio ผู้ชนะรางวัล Kids Choice Award ถึง 2 ครั้ง ภาพยนตร์ดังกล่าวอำนวยการสร้างโดย Ryan Kavanaugh ผู้ได้รับการเสนอชื่อให้เข้าชิง EGOT (Emmy, Grammy, Oscar และ Tony) และกำกับโดย F. Javier Gutierrez

Kavanaugh ได้นำเสนอภาพยนตร์มากกว่า 200 เรื่องและรายการทีวีโชว์ 40 รายการให้กับผู้ชมทั่วโลกมาแล้ว และนี่จะเป็นภาพยนตร์เรื่องที่สองที่จะเข้าจดทะเบียนในตลาดหลักทรัพย์เพื่อความบันเทิง esx.io

F. Javier Gutiérrez ผู้กำกับภาพยนตร์สยองขวัญ (เช่น Before the Fall, Rings) ผู้มีวิสัยทัศน์ที่ได้รับรางวัลชนะเลิศจะเข้ามารับหน้าที่กำกับภาพยนตร์เรื่องนี้ Home School นับเป็นการเปิดตัวภาพยนตร์คนแสดงครั้งแรกของ D’Amelio ซึ่งเป็นดาวติ๊กต็อกคนแรกที่มีผู้ติดตามถึง 100 ล้านคนบนแพลตฟอร์ม โดยการถ่ายทำมีกำหนดจะเริ่มในเดือนกรกฎาคม 2022

Charli โด่งดังเป็นพลุแตกบนติ๊กต็อกไปทั่วโลกหลังจากโพสต์วิดีโอการเต้นในปี 2019 ตั้งแต่กลายเป็นดาวดังของแอปดังกล่าว Charli ก็ยังได้ประสบความสำเร็จในด้านอื่น ๆ อีกด้วย ไม่ว่าจะเป็นการปรากฏตัวในโฆษณา Super Bowl ปี 2020 ของ Sabra Hummus และได้เต้นในมิวสิกวิดีโอของ Jennifer Lopez ในเดือนกันยายนปีที่แล้ว Hulu ได้เปิดตัว D’Amelio Show ซึ่งเป็นสารคดีซีรีส์ที่นำแสดงโดย Charli และครอบครัวของเธอ ซึ่งได้รับเลือกให้ทำเป็นซีซันที่สองอีกด้วย Charli ได้ร่วมสร้างไลน์เสื้อผ้า Social Tourist ของเธอเอง และเคยร่วมงานกับแบรนด์แฟชั่นรายใหญ่หลายราย เช่น Louis Vuitton และ Prada นอกจากนี้ Charli ยังเป็นดาราที่อายุน้อยที่สุดที่ปรากฏในรายชื่อ NEXT ของนิตยสาร Time

ในภาพยนตร์ Home School นี้ Charli จะรับบทเป็น ‘Mira’ เด็กสาววัย 17 ปีที่ย้ายไปอาศัยในต่างเมืองกับป้าของเธอหลังจากที่แม่ของเธอเสียชีวิต หลังจากมาถึงเมืองที่ดูสมบูรณ์แบบจนเหลือเชื่อแห่งนี้ ในไม่ช้า Mira ก็ได้ค้นพบว่าการตายของแม่และอนาคตของเธอนั้นมีความเชื่อมโยงกันอย่างเหนือธรรมชาติ

“ทันทีที่ได้อ่าน Home School ก็รู้เลยว่านี่เป็นภาพยนตร์สำหรับฉัน ฉันรู้สึกเชื่อมโยงกับทั้งตัวละคร Mira เนื้อเรื่อง สคริปต์ และทีมงาน ฉันรู้ว่าถ้าฉันจะแสดงหนังละก็ มันจะต้องเป็นอะไรที่สนุก แหวกแนว และสดใหม่” Charli กล่าว “แม้ว่าการแสดงในบทบาทดังกล่าวจะมีความท้าทายและผลักดันให้ฉันเรียนรู้การแสดงและกลายเป็น Mira ได้จริง ๆ แต่มันก็เป็นประสบการณ์ที่สนุกมากและฉันตั้งใจที่จะสร้างความสนุกทั้งในการถ่ายทำและในการรับชมด้วย แล้วก็ต้องการร่วมงานกับทีมงานที่ยอดเยี่ยมด้วยค่ะ”

ผู้กำกับ F. Javier Gutiérrez กล่าวอธิบายว่า “ตอนที่ผมกับ Ryan ได้พบกันระหว่างการพัฒนา The Crow เวอร์ชันรีเมคกับ Luke Evans พวกเรารู้ดีว่าเรายังอยากจับมือร่วมงานด้านการสร้างสรรค์ต่อไปอีก ผมตื่นเต้นมาก ๆ ที่ Home School นั้นถือเป็นการสร้างโปรเจ็กต์อย่างเป็นทางการครั้งแรกของเราร่วมกัน” “ด้วยภาพที่น่าดึงดูดและองค์ประกอบทางจิตวิทยาที่แข็งแกร่ง ผมคิดว่า Home School มีศักยภาพที่จะกลายเป็นภาพยนตร์โมเดิร์นคลาสสิกได้เลย ผมรอที่จะได้ร่วมงานกับ Charli และทีม Proxima แทบจะไม่ไหวแล้วล่ะครับ”

Gutiérrez เป็นผู้ได้รับการเสนอชื่อเข้าชิงรางวัล European Fantastic Film Award ถึง 2 ครั้ง ภาพยนตร์สยองขวัญที่สร้างชื่อเสียงโด่งดังให้กับเขาก็คือเรื่อง Rings ซึ่งเป็นภาคที่สามของแฟรนไชส์ The Ring โดยเปิดตัวเป็นอันดับ 2 บนยูเอสบ็อกซ์ออฟฟิศและได้รับการยกย่องจาก Koji Suzuki ผู้เขียนนวนิยาย The Ring ภาพยนตร์สั้นเรื่อง Brasil ของเขาได้รับรางวัลเกียรติยศสูงสุดและรางวัลมากมาย ซึ่งรวมถึงการคว้ารางวัล Universal Studios Film Master Award สาขา Best European Director ด้วย ภาพยนตร์เรื่องนี้ได้รับความสนใจจากอุตสาหกรรมในสหรัฐฯ หลังจากที่ได้มีการฉายรอบปฐมทัศน์ในอเมริกาเหนือที่งาน AFI Fest โดยรั้งอันดับที่ 3 ของ Hollywood International Watchlist ในปีเดียวกันนั้นเอง Before the Fall ก็ได้รับข้อเสนอให้มีการรีเมคจาก Wes Craven ผู้สร้างภาพยนตร์ในตำนานผู้ล่วงลับไปแล้ว ในช่วงเริ่มต้นของเส้นทางอาชีพ Gutiérrez ได้สร้างชื่อเสียงให้กับตัวเองในฐานะผู้สร้างภาพยนตร์สยองขวัญเมื่อภาพยนตร์สั้นเรื่องแรกของเขา Brasil ซึ่งเขากำกับ เขียน และอำนวยการสร้างในปี 2002 ได้รับรางวัล Sitges Film Festival ซึ่งเป็นหนึ่งในเทศกาลระดับนานาชาติชั้นนำที่สุดของโลกซึ่งเน้นไปที่ผลงานแฟนตาซีและสยองขวัญ

Ryan Kavanaugh กล่าวว่า “เราได้พัฒนาโปรเจ็กต์นี้มาหลายปีเพื่อนำเสนอสิ่งใหม่และน่าตื่นเต้นมาสู่หน้าจอ” Kavanaugh กล่าวว่า “การที่ได้ Javier มากำกับและ Charli ร่วมแสดงนั้นถือว่าเป็นส่วนประกอบที่สมบูรณ์แบบ เราจะทำให้ ‘The Sixth Sense’ มาเจอกันกับ ‘Get Out’ ในหนังเรื่องนี้ครับ”

Home School เขียนโดย Casey Giltner ซึ่งเป็นผู้เขียนบทภาพยนตร์จากรัฐมินนิอาโปลิส โดยเธอได้เขียนบท On the First Day of Christmas ซึ่งได้รับการเสนอชื่อใน BloodList ปี 2021 และเพิ่งจะได้รับการคัดเลือกโดย Village Roadshow และ Brillstein Entertainment Partners Daniel Herther รองประธานอาวุโสฝ่ายการผลิตของ Proxima ซึ่งเป็นผู้ดูแลการพัฒนา Home School ก็จะรับหน้าที่ดำเนินการผลิตด้วยเช่นกัน Bobby Sarnevesht และ Marc, Heidi และ Dixie D’Amelio ซึ่งเป็นพันธมิตรของ Kavanaugh จะทำหน้าที่เป็นผู้อำนวยการสร้าง

Steve Cohen แห่ง UTA และ Kevin Yorn แห่ง Morris, Yorn, Barnes, Levine, Krintzman, Rubenstein, Kohner, Endlich & Gellman เป็นตัวแทนของ Charli D’Amelio Neil Sacker แห่ง Sacker Entertainment Law เป็นตัวแทนของ Proxima และ Kavanaugh Michael Sheresky แห่ง UTA และ Nick Shumaker จาก Anonymous Content เป็นตัวแทนของ F. Javier Gutiérrez Stephen Clark จาก Lichter Grossman Nichols Adler Feldman & Clark ได้เจรจาข้อตกลงในนามของ F. Javier Gutiérrez

เกี่ยวกับ Proxima และ Ryan Kavanaugh
Ryan Kavanaugh เป็นผู้ก่อตั้ง Proxima Media และผู้ถือหุ้นที่มีอำนาจควบคุมของ Triller เขาเป็นหนึ่งในผู้บริหารที่ประสบความสำเร็จมากที่สุด มีผลงานมากที่สุด และได้รับยกย่องมากที่สุดในประวัติศาสตร์ของวงการบันเทิง ด้วยการนำโมเดลทางการเงินอันชาญฉลาดมาใช้สนับสนุนทางการเงินของภาพยนตร์ ทำให้เขาได้รับการขนานนามว่าเป็นผู้สร้าง “Moneyball สำหรับภาพยนตร์” เขาผลิต จัดจำหน่าย และ/หรือจัดโครงสร้างทางการเงินให้กับภาพยนตร์มากกว่า 200 เรื่อง ซึ่งสร้างรายได้จากบ็อกซ์ออฟฟิศทั่วโลกมากกว่า 20,000 ล้านดอลลาร์สหรัฐฯ และได้รับการเสนอชื่อเข้าชิงรางวัลออสการ์ทั้งสิ้น 60 เรื่อง เขาเป็นผู้ผลิตภาพยนตร์ที่ทำรายได้สูงสุดตลอดกาลอันดับที่ 25 ผลงานต่าง ๆ ของเขาได้แก่ Fast and Furious 2-6, 300, Social Network, Limitless, Fighter, Talladega Nights, Step Brothers และ Mama Mia! Kavanaugh และ Proxima เป็นผู้บุกเบิกข้อตกลงทางการเงินรูปแบบใหม่ให้กับ Marvel หลังจากที่ล้มละลาย ทำให้สตูดิโอและโครงสร้างทางการเงินเดินหน้าและนำไปสู่การเป็น Marvel Cinematic Universe เขาสร้างหมวดหมู่ SVOD (สตรีมมิง) กับ Netflix ซึ่งทำให้มูลค่าการตลาดของบริษัทเพิ่มขึ้นจาก 2 ดอลลาร์สหรัฐฯเป็น 1 หมื่นล้านดอลลาร์สหรัฐฯ Kavanaugh เป็นผู้ก่อตั้งร่วมของ Triller ซึ่งเป็นหนึ่งในสามแพลตฟอร์มสำหรับครีเอเตอร์ที่เติบโตเร็วที่สุด เมื่อไม่นานมานี้เขายังได้เป็นผู้นำการเข้าซื้อกิจการ การควบรวมกิจการ และการเปิดตัวใหม่ของแอปโซเชียลมีเดียและเพลง

นอกจากนี้ เขายังได้สร้างบริษัทโทรทัศน์ที่ทรงอิทธิพล ซึ่งปัจจุบันเป็นที่รู้จักกันในชื่อ Critical Content โดยเป็นบริษัทผลิตรายการยอดนิยมอย่าง Catfish ทาง MTV และ Limitless ทาง CBS ซึ่งเขาได้ขายไปในราคา 200 ล้านเหรียญสหรัฐฯ โดยบริษัทดังกล่าวมีละครโทรทัศน์ 40 เรื่อง ใน 19 เครือข่ายก่อนที่จะขายไป Kavanaugh ประสบความสำเร็จและได้รับรางวัลมากมาย ตั้งแต่ Producer of the Year Award ของ Variety ไปจนถึง Leadership Award ของ The Hollywood Reporter นอกจากนี้ยังได้รับรางวัลตั้งแต่รางวัล 40 Under 40 Most Influencely People in Business ของ Fortune ตลอดจน Fortune 400 ของ Forbes, Billion-Dollar Producer ของ Daily Variety และ the 100 Most Influential People in the World ของ Vanity Fair

เกี่ยวกับ Entertainment Stock Exchange (“ESX”)
Entertainment Stock X (ESX) เป็นแพลตฟอร์มรายแรกที่ช่วยให้ผู้ใช้และแฟน ๆ สามารถลงทุนในโปรเจ็กต์ภาพยนตร์และความบันเทิงต่าง ๆ ผ่าน Jobs Act ซึ่งเป็นแพลตฟอร์มนวัตกรรมสำหรับการจัดหาเงินทุนในด้านความบันเทิง บริษัทจะช่วยเติมเต็มความต้องการในการจัดหาเงินทุนที่มีรูปแบบใหม่และมีประสิทธิภาพมากขึ้นให้กับผู้สร้างภาพยนตร์ ESX ช่วยให้ผู้สร้างภาพยนตร์สามารถสร้างความสัมพันธ์ทางการตลาดที่มีคุณค่ากับแฟน ๆ ได้โดยตรง และทำให้แฟน ๆ สามารถลงทุนในภาพยนตร์ได้เป็นครั้งแรก ดูข้อมูลเพิ่มเติมได้ที่ ESX.io

ติดต่อด้านสื่อ

Michelle Vieyra
Jive PR + Digital
202-415-7714
michelle@jiveprdigital.com
www.jiveprdigital.com

Posted on

Isuzu Australia Limited drives forward with HERE Technologies for navigation services

ISUZU-F-SERIES-NAV1-SCREEN

Isuzu F Series HERE Navigation Screen

  • Isuzu Australia Limited (IAL) has deployed HERE Navigation in its new 2022 model year F Series, FX Series and FY Series trucks sold in Australia.
  • HERE Navigation enables IAL to add enhanced navigation services to its market leading medium duty and heavy-duty model offering.

April 28, 2022

Melbourne – Isuzu Trucks, the market leading heavy commercial vehicle brand in Australia, today announced that it has deployed HERE Navigation, an off-the-shelf navigation solution for embedded in-vehicle infotainment (IVI) platforms, in its new 2022 model year F Series, FX Series and FY Series trucks sold in the country. HERE Navigation optimizes Isuzu’s fleet operations with a connected in-vehicle navigation system from HERE Technologies, the leading location data and technology platform.

According to Isuzu’s Future of Trucking Report[1], fleet operators are seeking increased safety and business efficiency dividends from the technology incorporated in their road transport equipment.

With the new 2022 F Series, FX Series and FY Series trucks equipped with HERE Navigation, Isuzu truck drivers are able to receive the latest, updated and accurate maps, live traffic, and recommended truck routes to complete their jobs, by using mobile phone data from a tethered smartphone. This fully integrated solution will be deployed on Isuzu’s embedded IVI platform – the MyIsuzu Co-Pilot, so drivers receive guidance on the go for safe driving.

“HERE Navigation gives us the flexibility and agility required to offer one of the most interactive and intuitive navigation experiences on the market. The accurate maps and location data ensure that our operators have the latest route and navigation information available,” said Grant Cooper, Chief of Strategy at IAL.

“When it comes to connectivity, Isuzu strives to be flexible and offer our customers the right data to meet their specific business needs. From a navigation standpoint, HERE Navigation allows us to do just that with an innovative approach.”

Daniel Antonello, General Manager of Australia and New Zealand at HERE Technologies said, “The Australian truck and road transportation industry is going through major changes exacerbated by the pandemic. With road freight demand expected to increase in the coming years, it’s important that we leverage the best location technology to ensure that drivers are driving safely and efficiently. We’re proud that HERE is able to support Isuzu as they continue to enhance its product offerings in Australia and cement their position as the country’s truck market leader.”

Media contacts
Isuzu Australia Limited
Sam Gangemi
Marketing and Advertising Manager
+61 407 837 977
sam.gangemi@isuzu.net.au

HERE Technologies
Camy Cheng
+65 9088 4127
Camy.cheng@here.com

About HERE Technologies
HERE, the location data and technology platform, moves people, businesses and cities forward by harnessing the power of location. By leveraging our open platform, we empower our customers to achieve better outcomes – from helping a city manage its infrastructure or a business optimize its assets to guiding drivers to their destination safely. To learn more about HERE, please visit www.here.com and http://360.here.com.

About Isuzu Trucks
Isuzu Truck’s promise to deliver a premium product to the Australian market has been proudly and consistently upheld. The measure of our commitment is reflected in the number of trucks on the road that bear our marque, and the number of successful companies relying on Isuzu trucks every day. When we talk about reliability, we’re not just talking about trucks, but also about people and indeed our entire philosophy. In addition to our in-house Customer Care Centre, customers also have access to an extensive range of service and support programs designed to ensure that Isuzu truck ownership is a positive and rewarding experience for all concerned.

[1] Future of Trucking Report: The Road Ahead, Isuzu Truck

Attachments

Posted on

Amlan International Launches Two New Natural Alternatives to Antibiotics for Poultry and Livestock

  • Amlan has expanded its broad portfolio of animal health feed additives to include a natural alternative to anticoccidial drugs and vaccines and a natural pathogen control product for antibiotic-free production.
  • Increasing demand for antibiotic-free production has created the need for solutions like Phylox® Feed and NeutraPath® that can reduce the negative health and production effects of enteric disease.
  • The new products are commercially available in select international markets and can be used alone or in combination with products from Amlan’s comprehensive range of mineral-based feed additives.

CHICAGO, April 27, 2022 (GLOBE NEWSWIRE) — The removal of in-feed antibiotics from poultry and livestock production has left a huge gap in the protection of animals from the devastating effects of enteric disease. To help producers recapture this protection, Amlan International, the animal health business of Oil-Dri® Corporation of America, has launched two new natural products — Phylox® Feed and NeutraPath® — that help optimize intestinal health and production economics in the absence of antibiotics.

Phylox Feed is a natural alternative to anticoccidial drugs and vaccines that can help producers increase profitability. Coccidiosis, caused by Eimeria species, is an enteric disease that can have a significant economic impact on animal protein production. The synergistic blend of bioactive phytochemicals in Phylox work together with multiple modes of action to damage Eimeria cell structure and function while strengthening intestinal integrity and boosting immunity. Phylox can be effective for full-time use or in rotation, and/or in a bio-shuttle program when resistance is a concern. In addition, Phylox does not need to be withdrawn from feed prior to slaughter. Phylox is an ideal solution for all poultry species, including broilers, egg layers and broiler breeders, all of which can be sensitive to fungal and bacterial toxins during grow-out and egg production when exposed to fecal oocysts that are being shed as coccidia cycle. Research has shown that Phylox can be fed concurrently with anticoccidial vaccines, preventing disease breakthrough while immunity is being developed by the bird without interfering with vaccine efficacy. 

“The most important goal for producers is to keep animals healthy. Producers grow animals to a certain size, and they don’t want to lose them in the last few days of their growth development,” said Fred Kao, VP of Global Sales for Amlan. “The launch of Phylox and NeutraPath will be a huge benefit to the animal protein industry. Animals can remain healthy and reach their full potential, naturally.”

NeutraPath is a natural pathogen control product for antibiotic-free production that uses multiple modes of action to increase livability and improve feed conversion. Using a proprietary and co-active blend of essential oils, fatty acids and Amlan’s proprietary mineral technology, NeutraPath reduces pathogenic bacterial load and colonization, and improves intestinal health and structural integrity, all of which contribute to improved performance and increased production yields.

“Managing enteric disease without antibiotics has placed extra pressure on nutritionists and veterinarians to find natural solutions that can achieve the same level of performance observed with antibiotic use,” said Dr. Wade Robey, VP of Marketing and Product Development for Amlan. “NeutraPath has answered the call for a natural product that targets pathogens and the toxins they produce — and it improves intestinal health, as well. It’s the natural alternative to antibiotics that the animal protein industry has been waiting for.”

NeutraPath can be used to protect the intestinal health of all livestock species. The Journal of Animal Science recently published a study by UC Davis researchers on the effects of NeutraPath in weaned pigs challenged with enterotoxigenic E. coli. NeutraPath reduced the incidence of severe diarrhea, enhanced feed efficiency during the last week of the study and modified fecal and ileal mucosa microbiota diversity.

Both of the new products can be used individually or in a program with Amlan’s mineral-based products, like Calibrin®-Z and patented Varium® and NeoPrime®, to help support gut health and improve productivity and efficiency.

Phylox and NeutraPath are commercially available in select international markets. While not available for sale in the United States, North American customers interested in NeutraPath and Phylox can contact Amlan for more information on similar feed additives available in the U.S. that were developed to optimize intestinal health in production animals.

Amlan invests heavily in R&D to produce well-validated products both in vitro and in animals, and they are also working directly with customers to assess the commercial performance of their new products. Producers interested in testing the products for themselves can contact Amlan at info@amlan.com.

Company Information

Amlan is the animal health business of Oil-Dri Corporation of America, leading global manufacturer and marketer of sorbent minerals. Oil-Dri leverages over 80 years of expertise in mineral science to selectively mine and process their unique mineral for consumer and business-to-business markets. Oil-Dri Corporation of America doing business as “Amlan International” is a publicly traded stock on the New York Stock Exchange (NYSE: ODC). Amlan International sells feed additives across the world. Product availability may vary by country; associated claims do not constitute medical claims and may differ based on government requirements.

Reagan Culbertson
Media Contact
press@amlan.com

Proudly powered by WordPress